Reviva Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Reviva Pharmaceuticals Holdings
RVPH Stock  USD 0.29  0.01  3.33%   
Reviva Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Reviva Pharmaceuticals' valuation are provided below:
Market Capitalization
34.2 M
Earnings Share
(0.43)
We have found one hundred seven available trending fundamental ratios for Reviva Pharmaceuticals, which can be analyzed and compared to other ratios and to its competitors. Traders should compare all of Reviva Pharmaceuticals recent fundamentals against the fundamentals between 2010 and 2026 to make sure the company is sustainable this year. The current Market Cap is estimated to decrease to about 44 M. Enterprise Value is estimated to decrease to about 33.7 M
Check Reviva Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Reviva Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 37.2 M, Interest Expense of 15.8 K or Selling General Administrative of 4.6 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 69.77. Reviva financial statements analysis is a perfect complement when working with Reviva Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Reviva Stock
Check out the analysis of Reviva Pharmaceuticals Correlation against competitors.

Reviva Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets18.7 M14 M42.2 M
Slightly volatile
Total Current Liabilities17.6 M16.8 M7.9 M
Slightly volatile
Accounts Payable7.6 M7.2 M1.8 M
Slightly volatile
Cash And Short Term Investments18.2 M12.1 M41.8 M
Slightly volatile
Common Stock Shares Outstanding40 M38.1 M11.4 M
Slightly volatile
Short Term Investments52.2 M58.7 M64.1 M
Slightly volatile
Liabilities And Stockholders Equity18.7 M14 M42.2 M
Slightly volatile
Total Liabilities9.8 M16.9 M8.1 M
Slightly volatile
Total Current Assets18.6 M13.2 M42.1 M
Slightly volatile
Common Stock5.6 K5.4 K1.7 K
Slightly volatile
Property Plant Equipment731532937
Slightly volatile
Short and Long Term Debt Total391.7 K412.3 K2.4 M
Slightly volatile
Current Deferred Revenue2.2 M2.5 M2.7 M
Slightly volatile
Cash17.2 M15.5 M7.4 M
Slightly volatile
Non Currrent Assets Other895.5 K942.7 K24.1 M
Pretty Stable
Common Stock Total Equity8481.1 K747
Slightly volatile
Non Current Liabilities Total76.1 K80.1 K1.5 M
Slightly volatile
Other Stockholder Equity117.5 M189.8 M94.5 M
Slightly volatile
Property Plant And Equipment Gross50.4 K48 K18.4 K
Slightly volatile
Short and Long Term Debt391.7 K412.3 K2.4 M
Slightly volatile
Capital Stock4 K4.2 K17.1 M
Slightly volatile
Short Term Debt391.7 K412.3 K2.4 M
Slightly volatile
Other Liabilities774.4 K510.7 K1.5 M
Slightly volatile
Other Current Assets820.5 K1.4 M390.2 K
Slightly volatile

Reviva Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization37.2 M35.4 M8.5 M
Slightly volatile
Interest Expense15.8 K16.6 K424.2 K
Slightly volatile
Selling General Administrative4.6 M9.1 M2.6 M
Slightly volatile
Research Development27.7 M26.3 M8.3 M
Slightly volatile
Total Operating Expenses37.2 M35.4 M11.2 M
Slightly volatile
Income Tax Expense23.6 K22.4 K6.9 K
Slightly volatile
Tax Provision11.9 K22.4 K6.3 K
Slightly volatile
Interest Income252.7 K415.6 K117.7 K
Slightly volatile
Reconciled Depreciation91.4996.3450
Slightly volatile
Cost Of Revenue579.8 K652.3 K712 K
Slightly volatile

Reviva Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Other Cashflows From Financing Activities163171991 K
Pretty Stable
Depreciation91.4996.39.5 K
Slightly volatile
Total Cash From Financing Activities17.2 M27.2 M9.1 M
Slightly volatile
End Period Cash Flow14.8 M15.5 M7.4 M
Slightly volatile
Begin Period Cash Flow14.8 M26.9 M7.2 M
Slightly volatile
Issuance Of Capital Stock19.9 M26.7 M8.2 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Average Payables3.5 M3.3 M1.2 M
Slightly volatile
Payables Turnover0.580.650.7067
Slightly volatile
Cash Per Share0.440.4717.4113
Slightly volatile
Days Payables Outstanding406457499
Slightly volatile
Income Quality0.661.010.742
Slightly volatile
Current Ratio1.11.161.5606
Slightly volatile
Interest Debt Per Share0.01570.01650.266
Pretty Stable
Debt To Assets0.03230.034852
Slightly volatile
Days Of Payables Outstanding406457499
Slightly volatile
Ebt Per Ebit1.431.121.39
Slightly volatile
Quick Ratio1.11.161.5606
Slightly volatile
Net Income Per E B T0.80.90.9828
Slightly volatile
Cash Ratio1.011.061.498
Slightly volatile
Debt Ratio0.03230.034852
Slightly volatile

Reviva Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap44 M54 M38.1 M
Slightly volatile
Enterprise Value33.7 M42.3 M31.5 M
Slightly volatile

Reviva Fundamental Market Drivers

Reviva Upcoming Events

4th of April 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Reviva Pharmaceuticals Financial Statements

Investors use fundamental indicators, such as Reviva Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Although Reviva Pharmaceuticals' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Current Deferred Revenue2.5 M2.2 M
Cost Of Revenue652.3 K579.8 K

Currently Active Assets on Macroaxis

VGIAXVanguard Growth And
XARSPDR SP Aerospace
XARSPDR SP Aerospace
XARSPDR SP Aerospace
ASMLASML Holding NV
When determining whether Reviva Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Reviva Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Reviva Pharmaceuticals Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Reviva Pharmaceuticals Holdings Stock:
How To Invest In Reviva
Details
Is Reviva Stock a good investment?
Details
What is Reviva Pharmaceuticals' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Reviva Pharmaceuticals Correlation against competitors.
You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is there potential for Biotechnology market expansion? Will Reviva introduce new products? Factors like these will boost the valuation of Reviva Pharmaceuticals. Anticipated expansion of Reviva directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about Reviva Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.43)
Return On Assets
(1.30)
Return On Equity
(9.16)
The market value of Reviva Pharmaceuticals is measured differently than its book value, which is the value of Reviva that is recorded on the company's balance sheet. Investors also form their own opinion of Reviva Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Reviva Pharmaceuticals' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Reviva Pharmaceuticals' market value can be influenced by many factors that don't directly affect Reviva Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
It's important to distinguish between Reviva Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Reviva Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Reviva Pharmaceuticals' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY